Price Chart

Profile

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.
URL https://www.revmed.com
Investor Relations URL https://ir.revmed.com/
HQ State/Province California
Sector Health Care
Industry Biotechnology
Equity Style Small Cap/Blend
Next Earnings Release Nov. 06, 2024
Last Earnings Release Aug. 07, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.
URL https://www.revmed.com
Investor Relations URL https://ir.revmed.com/
HQ State/Province California
Sector Health Care
Industry Biotechnology
Equity Style Small Cap/Blend
Next Earnings Release Nov. 06, 2024
Last Earnings Release Aug. 07, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A